Gland Pharma tanks 20%,
Gland Pharma tanks 20%, hits record low on weak Q4 results
Revenue declined 29% YoY due to lower offtake of the key products in developed as well as domestic markets and due to Production line shut down in Pashamylaram Penems facility due to line upgradation.
Revenue declined 29% YoY due to lower offtake of the key products in developed as well as domestic markets and due to Production line shut down in Pashamylaram Penems facility due to line upgradation.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.